



30 November 2020

ASX ANNOUNCEMENT

Notification of Investor Conference Call: Meta-Analysis Publication

Brisbane, Australia – ImpediMed Limited (ASX:IPD) invites investors to join a conference call at 9.00am AEDT on Monday 30 November 2020.

The call will be hosted by:

- Richard Carreon, Managing Director and CEO, ImpediMed
- Catherine Kingsford, SVP Medical Affairs, ImpediMed
- Dr Chirag Shah, Radiation Oncologist and Director of Clinical Research and Director of Breast Radiation Oncology in the Department of Radiation Oncology at the Cleveland Clinic

To pre-register please follow this link:

<https://s1.c-conf.com/diamondpass/10011251-sat182.html>

You will receive a calendar notification with dial in details and a PIN for fast track access to the call.

Approved for release by the Managing Director and CEO, Mr Richard Carreon.

Contact Details

Investor relations Contact:

Mike Bassett, ImpediMed
T: +61 407 431 432
E: mbassett@impedimed.com

Media Contact:

Kyahn Williamson, WE Communications
T: +61 3 8866 1200
E: kwilliamson@we-worldwide.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally.

For more information, visit www.impedimed.com.